Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1987 Apr;31(4):605-9.
doi: 10.1128/AAC.31.4.605.

Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers

Comparative Study

Single-dose accumulation pharmacokinetics of tobramycin and netilmicin in normal volunteers

N E Winslade et al. Antimicrob Agents Chemother. 1987 Apr.

Abstract

The two-compartment tissue accumulation pharmacokinetics of tobramycin and netilmicin were compared in 11 normal volunteers by using a crossover design. After each 1.0-mg/kg (body weight) dose, serum was collected for 96 h, and complete 24-h urine collections were obtained for a total of 30 days. Two months of washout were required before crossover. Concentrations in serum and urine were measured by radioimmunoassay, and concentrations in serum and urinary excretion rates were simultaneously fitted to a two-compartment pharmacokinetic model. Netilmicin exhibited significantly lower total body clearance (48 versus 90 ml/min) and longer terminal elimination half-life (161 versus 96 h) than tobramycin. As a result of these pharmacokinetic differences, the predicted tissue accumulation of netilmicin at steady state was significantly higher than that of tobramycin (P less than 0.05). Relative rates of aminoglycoside nephrotoxicity probably depend on both the differential tissue uptake (accumulation) and the concentration of the aminoglycoside which produces intracellular toxicity. Because the steady-state tissue accumulation of netilmicin is nearly 2.5 times greater than that of tobramycin, its potency in the production of intracellular toxicity needs to be that much less for the two agents to produce the same incidence of clinical nephrotoxicity.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Clin Pharmacol Ther. 1973 May-Jun;14(3):396-403 - PubMed
    1. J Pharmacol Exp Ther. 1986 Feb;236(2):470-5 - PubMed
    1. J Pharmacokinet Biopharm. 1977 Dec;5(6):559-77 - PubMed
    1. Antimicrob Agents Chemother. 1978 Feb;13(2):170-6 - PubMed
    1. Antimicrob Agents Chemother. 1978 Apr;13(4):649-56 - PubMed

Publication types